证券简称：康缘药业 证券代码：600557 公告编号：2025-048 江苏康缘药业股份有限公司 关于选举第八届董事会职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏康缘药业股份有限公司（以下简称"公司"）第八届董事会第二十二次会议 和 2025 年第一次临时股东会审议通过了《关于取消监事会并修改<公司章程>的议 案》。根据修订后的《公司章程》的规定，公司董事会设职工代表董事一名，由职 工代表大会民主选举产生。 公司于 2025 年 12 月 29 日召开职工代表大会，会议民主选举王振中先生（简历 附后）为公司第八届董事会职工代表董事，任期自本次职工代表大会选举通过之日 起至公司第八届董事会任期届满之日止。 特此公告。 江苏康缘药业股份有限公司董事会 2025 年 12 月 29 日 1 附件： 江苏康缘药业股份有限公司 职工代表董事简历 王振中：1968 年 3 月出生，中药学博士，研究员级高级工程师。1993 年进入公 司，历任质量管理部部长、中药研究所副所长、化学药研究所所长、研发中心副主 任兼药 ...

关于江苏康缘药业股份有限公司 2025 年第一次临时股东会的法律意见书 江苏康缘药业股份有限公司： 康缘药业 2025 年第一次临时股东会 法律意见书 江苏世纪同仁律师事务所 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》《上市公司股东会规则》《上海证券交易所上市公司自律监管指 引第 1 号——规范运作》等法律、法规和规范性文件以及《公司章程》的规定， 本所受公司董事会的委托，指派本所律师出席公司 2025 年第一次临时股东会， 并就本次股东会的召集、召开程序、出席会议人员资格、召集人资格、表决程序 以及表决结果等事项的合法有效性出具法律意见。 为出具本法律意见书，本律师对本次股东会所涉及的有关事项进行了审查， 查阅了相关会议文件，并对有关问题进行了必要的核查和验证。 本律师同意将本法律意见书随公司本次股东会决议一并公告，并依法对本法 律意见书承担相应的责任。 本律师根据相关法律、法规和规范性文件的要求，按照律师行业公认的业务 标准、道德规范和勤勉尽责精神，出具法律意见如下： 一、关于本次股东会的召集和召开 1、本次股东会由公司董事会召集 本次股东会由董事会召集。2025 ...

证券代码：600557 证券简称：康缘药业 公告编号：2025-047 江苏康缘药业股份有限公司 2025年第一次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 322 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 254,983,011 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 45.0373 | | 份总数的比例（%） | | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由公司董事会召集，副董事长王振中先生主持，会议采取现场投票 和网络投票相结合的表决方式。会议的召集、召开和表决符合《公司法》及《公 (一) 股东会召开的时间：2025 年 12 月 29 日 (二) 股东会召开的地点：连云港经济技术开发区江宁工业城公司会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况 ...

Core Insights - The article highlights the surge in demand for traditional Chinese medicine, particularly in the context of the ongoing H3N2 influenza outbreak in China, with a positive detection rate exceeding 30% and H3N2 subtype accounting for over 95% of cases [1][2] Industry Overview - The flu season has officially begun in China, with activity levels expected to peak between mid-December and early January [1] - The demand for flu medications has skyrocketed, with JD Health reporting a more than 13-fold year-on-year increase in sales of flu-related drugs since November [1] Company Performance - Kangyuan Pharmaceutical (600557.SH) is responding to the increased market demand by ramping up production of its products, including Jin Zhen Oral Liquid, which is expected to see a market demand rebound in Q4 [1][3] - The company has established a comprehensive product portfolio covering prevention, treatment, and rehabilitation, with key products like Heat Toxicity Ning Injection and Jin Zhen Oral Liquid effectively addressing core flu symptoms [2][3] - Oral liquid products have become the company's largest revenue source, generating 1.359 billion yuan in revenue in the first three quarters of 2025, accounting for 58% of total revenue, a significant increase from 20% in 2024 [2] Market Dynamics - The sales of traditional Chinese medicines such as Ganmao Ling Granules and Xiao Chai Hu Granules have seen over 100% month-on-month growth, indicating strong consumer preference [2] - The company is well-positioned to capitalize on the current market environment, which is seen as a critical opportunity for performance recovery, particularly with the ongoing flu season [3]

Core Insights - The flu epidemic in China has reached a high prevalence level, with a positive rate of over 51% among flu-like cases in emergency departments, leading to a surge in demand for antiviral drugs [1][3] - Companies such as NuoTai Bio, Kangyuan Pharmaceutical, and China Resources Sanjiu have seen significant increases in demand for respiratory products, with some experiencing supply shortages [1][3] - The market for antiviral drugs is shifting towards a combination of classic medications and innovative therapies, with a notable increase in demand for traditional Chinese medicine products [6][7] Group 1: Market Demand and Trends - The demand for flu antiviral drugs has surged, with purchases of Mabalosavir increasing by over 600% in the past two weeks [1] - The flu season is expected to peak in mid-December, with the H3N2 subtype being the dominant strain [3] - Companies are implementing priority supply mechanisms to meet the rising demand for flu medications [3] Group 2: Product Performance and Innovation - Kangyuan Pharmaceutical has demonstrated strong product synergy, with a comprehensive range of products covering the entire treatment process from acute symptoms to recovery [3][4] - Traditional Chinese medicine products like Jinzhen Oral Liquid and Xingbei Cough Granules have seen order increases exceeding 100% [6] - The market is witnessing a shift towards a dual approach of classic and innovative therapies, enhancing the overall treatment landscape for respiratory diseases [6][7] Group 3: Strategic Positioning of Companies - Companies like Zhongsheng Pharmaceutical are positioning their innovative flu drugs to strengthen their market leadership in respiratory treatments [7] - The collaborative growth model driven by innovative products is enhancing the operational capabilities of domestic pharmaceutical companies [7] - The respiratory product system is expected to maintain its strategic value in managing flu seasons and respiratory diseases in the future [7]

Core Insights - The article highlights the rising incidence of respiratory infectious diseases, particularly influenza, driven by the H3N2 virus, leading to increased outpatient visits and temporary school closures in China [1] - Traditional Chinese medicine (TCM) is emphasized for its unique approach to enhancing the body's immune response rather than solely targeting pathogens, making it particularly suitable for children and adolescents [1] - Jin Zhen Oral Liquid, developed by Kangyuan Pharmaceutical, is noted for its broad-spectrum antiviral and anti-inflammatory properties, showing a total effective rate of 97% in treating pediatric respiratory infections [2][4] Company Performance - Jin Zhen Oral Liquid has been included in several authoritative treatment guidelines, and its recent clinical trial application for pediatric influenza has been approved, indicating potential market expansion [4] - In the first half of 2025, Kangyuan Pharmaceutical reported a revenue of 1.642 billion yuan and R&D expenses of 247 million yuan, with an R&D expense ratio of 15.02%, positioning it as a leader among traditional Chinese medicine companies [5] - The company has actively responded to market demands by ensuring the supply of its core products and has applied for eight new drug approvals this year, with recent successes in obtaining clinical trial approvals for innovative TCM products [5][6] Market Position - Jin Zhen Oral Liquid holds over 16% market share in the pediatric cough and phlegm relief market, ranking first among top brands, reflecting its acceptance by both doctors and parents [4] - Kangyuan Pharmaceutical's other product, Sanhan Huashi Granules, has also shown significant efficacy in treating respiratory diseases, further enhancing the company's product portfolio [4][5] - The company is focused on modernizing and standardizing TCM, leveraging its technical advantages to expand market opportunities and drive sustainable growth [6]

Core Viewpoint - Kangyuan Pharmaceutical has initiated clinical trials for Longqi Capsules in accordance with supplementary material requirements and will disclose key information as per legal obligations [1] Group 1: Company Developments - The company is actively contributing to the macroeconomic strategy addressing population aging, focusing on traditional Chinese medicine [1] - Kangyuan has core products targeting health needs of the elderly, including treatments for cardiovascular diseases and bone injuries, such as Ginkgo Biloba Diterpene Injection and Tian Shu Capsules [1] - The company is also developing treatments for Alzheimer's disease, sleep disorders, and chronic obstructive pulmonary disease, with related products entering clinical stages [1] Group 2: Financial Performance - For the period from January to September 2025, Kangyuan Pharmaceutical reported revenue of 2.343 billion yuan, a year-on-year decrease of 24.59% (adjusted) [1] - The net profit attributable to the parent company was 200 million yuan, reflecting a year-on-year decline of 35.63% [1]

Core Viewpoint - Kangyuan Pharmaceutical has initiated clinical trials for Longqi Capsules in response to supplementary material requirements and will disclose key information regarding trial progress and review results in accordance with legal regulations [1] Group 1: Company Initiatives - The company is actively aligning with the macroeconomic strategy of an aging population, leveraging its strengths in traditional Chinese medicine to address health needs of the elderly [1] - Kangyuan Pharmaceutical has core products targeting age-related diseases, including Ginkgo Biloba Diterpene Injection, Tienshu Capsules/Tablets, and Tongsemai Capsules/Tablets [1] Group 2: Research and Development Focus - The company is expanding its research and development efforts in areas related to aging, including Alzheimer's disease, sleep disorders, and chronic obstructive pulmonary disease, with relevant products already in clinical stages [1]

Core Viewpoint - Kangyuan Pharmaceutical has recently received a drug registration certificate for Xiebaisan Granules from the National Medical Products Administration [2] Company Summary - Kangyuan Pharmaceutical announced the receipt of the drug registration certificate for Xiebaisan Granules on December 12 [2]

Core Viewpoint - Kangyuan Pharmaceutical (600557) has recently received a drug registration certificate for Xiebaisan granules from the National Medical Products Administration, indicating a significant regulatory approval for the company’s product aimed at treating pediatric cough and asthma due to lung heat [1] Group 1 - The drug Xiebaisan is indicated for clearing lung heat and alleviating cough and asthma symptoms in children [1] - The approval of the drug registration certificate represents a milestone for Kangyuan Pharmaceutical, potentially enhancing its product portfolio and market presence [1]